A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Anaveon AG
Study ID
NCT06470763
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ANV600 — DRUG
    ANV600 administered by intravenous (IV) infusion
  • ANV600 + pembrolizumab (KEYTRUDA®) — DRUG
    ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion

Study Details

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.

Key Dates

First listed
Jun 24, 2024
Start date
Jul 1, 2024
Status verified
Jul 2026
Primary completion
Jun 22, 2026
Completion
Jun 22, 2026

Study Design

Enrollment
63 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ANV600 single agent
  • Experimental: ANV600 in combination with pembrolizumab (KEYTRUDA®)

Primary Outcome Measure

Phase I dose escalation: Incidence of Dose Limiting Toxicities (DLT) with ANV600 single agent and in combination with pembrolizumab combination with pembrolizumab [ Time Frame: Day 1 up to 24 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Karmanos Cancer InstituteDetroitMichigan48201-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Detroit, MI

By research site
Karmanos Cancer Institute· Detroit, MIFox Chase Cancer Center· Philadelphia, PAMD Anderson Cancer Center· Houston, TX

Related Studies